LUND, Sweden, Aug. 31, 2022 /PRNewswire/ — The number of shares and votes in Cantargia AB (publ) has changed due to the recently completed rights issue (for further information, see the company’s press release on 12 August 2022). Through the rights issue, the number of shares and votes in Cantargia increased by 66,795,158. Today, on the last trading day of the month, there are in total 166,987,895 shares and votes in Cantargia.
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
This is information that Cantargia AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 12.30 CET on 31 August 2022.
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies – CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR – with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at https://cantargia.com/en/.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/7470/3622042/1620371.pdf Cantargia- new number of shares PR Eng 220831 Final
The content is by PR Newswire. Headlines of Today Media is not responsible for the content provided or any links related to this content. Headlines of Today Media is not responsible for the correctness, topicality or the quality of the content.